46 Introduction to Autism Spectrum Disorders
37 Vuong HE, Hsiao EY (2017). Emerging roles for the gut microbiome in autism
spectrum disorder. Biol. Psychiatry, 81 (5):411–23.
38 Persico AM, Napolioni V (2013). Urinary p‐cresol in autism spectrum
disorder. Neurotoxicol. Teratol., 36 82–90.
39 Gomes MP, Smedbol E, Chalifour A, et al. (2014). Alteration of plant
physiology by glyphosate and its by‐product aminomethylphosphonic acid: an
overview. J. Exp. Bot., 65 (17):4691–703.
40 Morley WA, Seneff S (2014). Diminished brain resilience syndrome: A modern
day neurological pathology of increased susceptibility to mild brain trauma,
concussion, and downstream neurodegeneration. Surg. Neurol. Int., 5 :97.
41 Chamak B (2010). Autism: overestimation of the genetic origins. Med. Sci.
(Paris), 26 :659–62.
42 Hallmayer J, Cleveland S, Torres A, et al. (2011). Genetic heritability and
shared environmental factors among twin pairs with autism. Arch. Gen.
Psychiatry, 68 (11):1095–102.
43 Tammimies K, Marshall CR, Walker S, et al. (2015) Molecular diagnostic yield
of chromosomal microarray analysis and whole‐exome sequencing in children
with autism spectrum disorder. JAMA, 314 (9):895–903.
44 Landrigan PJ (2010). What causes autism? Exploring the environmental
contribution. Curr. Opin. Pediatr., 22 :219–25.
45 Ortega García JA, Ferrís I, Tortajada J, López Andreu JA (2007). Paediatric
environmental health speciality units in Europe: integrating a missing element
into medical care. Int. J. Hyg. Environ. Health, 210 :527–9.
46 Betancur C (2011). Etiological heterogeneity in autism spectrum disorders:
more than 100 genetic and genomic disorders and still counting. Brain Res.,
1380 :42–77.
47 Hertz‐Picciotto I, Park HY, Dostal M, et al. (2008). Prenatal exposures to
persistent and non‐persistent organic compounds and effects on immune
system development. Basic Clin. Pharmacol. Toxicol., 102 :146–54.
48 Galic MA, Spencer SJ, Mouihate A, Pittman QJ (2009). Postnatal
programming of the innate immune response. Integr. Comp. Biol.,
49 (3):237–45.
49 Kubota T, Miyake K, Hariya N, Mochizuki K (2015). Epigenomic‐basis of
preemptive medicine for neurodevelopmental disorders. Curr. Genomics,
16 (3):175–82.
50 Ng SB, Bigham AW, Buckingham KJ, et al. (2010). Exome sequencing
identifies MLL2 mutations as a cause of Kabuki syndrome. Nat. Genet.,
42 :790–3.
51 Hoischen A, van Bon BW, Gilissen C, et al. (2010). De novo mutations of
SETBP1 cause Schinzel‐Giedion syndrome. Nat. Genet., 42 :483–5.
52 Miller DT, Shen Y, Weiss LA, et al. (2009). Microdeletion/duplication at
15q13.2q13.3 among individuals with features of autism and other
neuropsychiatric disorders. J. Med. Genet., 46 :242–8.